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Interaction between CD36 and FABP4 modulates adipocyte-
induced fatty acid import and metabolism in breast cancer
Jones Gyamfi 1,2, Joo Hye Yeo1, Doru Kwon1, Byung Soh Min3, Yoon Jin Cha4, Ja Seung Koo5, Joon Jeong6, Jinu Lee1 and
Junjeong Choi 1✉
Adipocytes influence breast cancer behaviour via fatty acid release into the tumour microenvironment. Co-culturing human
adipocytes and breast cancer cells increased CD36 expression, with fatty acid import into breast cancer cells. Genetic ablation of
CD36 attenuates adipocyte-induced epithelial-mesenchymal transition (EMT) and stemness. We show a feedforward loop between
CD36 and STAT3; where CD36 activates STAT3 signalling and STAT3 binds to the CD36 promoter, regulating its expression. CD36
expression results in metabolic reprogramming, with a shift towards fatty acid oxidation. CD36 inhibition induces de novo
lipogenesis in breast cancer cells. Increased CD36 expression occurs with increased FABP4 expression. We showed that CD36
directly interacts with FABP4 to regulate fatty acid import, transport, and metabolism. CD36 and FABP4 inhibition induces apoptosis
in tumour cells. These results indicate that CD36 mediates fatty acid import from adipocytes into cancer cells and activates
signalling pathways that drive tumour progression. Targeting CD36 may have a potential for therapy, which will target the tumour
microenvironment.
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INTRODUCTION
The tumour microenvironment is key to tumour growth. In breast
cancer, the role of adipocytes has gained enormous attention due
to their proximity to the developing breast tumour. Clinical studies
have associated breast cancer invasion of surrounding adipocytes
at the tumour margin, with poor patient outcomes1,2. Focus on
elucidating the mechanism by which adipocyte influence cancer
cell growth has identified two major mechanisms. Firstly,
adipocytes secrete adipocytokines (adipocyte-secreted growth
factors and cytokines), which activate growth-promoting signal-
ling pathways in tumour cells and drive various oncogenic
processes. Adipocyte-secreted interleukin-6 (IL-6) and leptin
reportedly induce and regulate epithelial–mesenchymal transition
(EMT) in cancer cells3–5. Adipocyte-secreted leptin activates
targets that enhance stem cell renewal and chemoresistance6,7.
Secondly, adipocytes release metabolites and biomolecules, which
remodel tumour cell metabolism to enhance tumour growth.
Energy metabolism reprogramming is a key hallmark of tumour
growth8,9. Adipocytes proximity to breast cancer cells allows
breast cancer cells to parasite on their energy substrates and
obtain metabolites, including lactate, glutamine and fatty acids,
which are limited in the growing tumour environment9–11. The
acquired metabolites maintain the metabolic needs and provide a
selective advantage for tumour survival and progression in the
harsh microenvironment. There are emerging studies into the
mechanisms of free fatty acid (FFA) import and metabolism in
breast cancer microenvironment, however, several aspects of the
process remain unexplored.
Fatty acid translocase/CD36 is a key membrane glycoprotein
involved in importing adipocyte-released fatty acid into breast
cancer cells12,13. CD36 is expressed in a wide range of cells,
including platelets, myocytes, monocytes, macrophages,
adipocytes and some epithelial cells12,13. The primary functions
of CD36 include fatty acid uptake, cell adhesion or a class B
scavenger receptor12,13. Recently, the functions of CD36 have
extended to include lipid metabolism, inflammatory response,
and cancer development12. Studies across various cancers
(gastric, oral squamous cell, prostate and ovarian) have high-
lighted the role of CD36 in fatty acid import into cancer cells and
fatty acid oxidation (FAO) regulation to enhance progression14–16.
The myriad of roles linked to CD36 indicate a context-dependent
function. In adipocyte-breast cancer cell interaction, CD36 plays a
role in reprogramming metabolism, with a shift towards
enhanced FAO11,13. Thus, CD36 may be a unique receptor for
fatty acid import and regulate various oncogenic processes.
However, the molecular mechanisms and regulators of CD36
activity in breast cancer cells remain largely unexplored. This
study aimed to explore the context-dependent role of CD36 in
adipocyte-breast cancer interaction. To this, we report an
increased CD36 expression in breast cancer tissues invading
surrounding adipose tissues and its tumour promoting function
in adipocyte-breast cancer cell interaction.
RESULTS
CD36 is key in adipocyte-released fatty acid import into breast
cancer cells
To explore the context-dependent role of CD36 in adipocyte-
breast cancer cell interaction, CD36 expression was examined in a
direct co-culture of breast cancer cells (MCF10A, MCF-7, BT-483,
HCC2218 and MDA-MB-468) and differentiated human adipocytes
(hADS) after 48 hours via qRT-PCR. CD36 expression increased in
the co-cultured cells, compared to the control groups (Fig. 1A).
The increased CD36 expression was higher in the luminal MCF-7
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and basal MDA-MB-468 cell lines, compared to the luminal BT-483
and HER2+ HCC2218 cell lines (Fig. 1A, B). In human tissue
microarray, consisting of normal and 180 human breast tumour
samples, immunohistochemistry (IHC) revealed weak or no CD36
expression in seven of the nine normal patient tissues. CD36
expression varied in tumour tissues, with 33 (18.3%) having weak
or no CD36 expression. Moderate CD36 staining was observed in
84 (46.7%) of tumour tissues and strong staining was observed in
63 (35%) of tumour tissues (Fig. 1C). Adipocyte infiltration by
tumour cells was present in 128 (71.1%) of tumour tissues, positive
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CD36 expression was present in 109 (60.5%) of tumour tissues
(Fig. 1C) with adipocyte infiltration. Weak or no CD36 expression
was present 19 (10.6) of tumour tissues with adipocyte infiltration
(Fig. 1C).
The direct role of CD36 in fatty acid import was investigated
by indirect co-culture of MCF-7 and MDA-MB-468 cells with
adipocyte-conditioned media, with/without 200 μM of the CD36
inhibitor Sulfosuccinimidyl oleate sodium (SSO). Oil red O
staining of co-cultured cells revealed phenotypic changes, with
tiny intracellular lipid droplet formation (Fig. 1D). Lipid
accumulation in cells increased from 12 h, after co-culture, and
peaked between 36 and 48 h (Fig. 1E, F). Expectedly, intracel-
lular glycerol and triglyceride contents significantly increased in
co-cultured cells (Fig. 1G and Supplementary Fig. 1), while CD36
inhibition decreased fatty acid accumulation (Fig. 1H, I and
Supplementary Fig. 1H–L). These results indicate the active role
of CD36 in fatty acid import in adipocyte-breast cancer cell
interaction.
CD36 mediates adipocyte-induced EMT emergence and stem
cell traits
To examine the molecular function of CD36 in adipocyte-breast
cancer cell interaction, we established stable CD36 expression
MCF-7 and MDA-MB-468 cell lines (CD36 expression cells). Stable
CD36-knockout MCF-7 and MDA-MB-468 cells, using two distinct
CRISPR-Cas gRNA targeting CD36 (CD36-knockout1 and CD36
knockout2). Control MCF-7 and MDA-MB-468 cell lines transfected,
with an empty pLVX-EIP plasmid (mock-CD36). The efficiency of
CD36 knockout and amplification were validated by western blot
and qRT-PCR (Supplementary Fig. 2).
Elevated CD36 expression is linked to fatty acid uptake and EMT
emergence15. We examined the association between increased
CD36 expression and the expression of EMT transcription factors
(EMT-TFs: TWIST1 and SNAIL) and EMT-related markers (EMT-RMs:
N-cadherin, E-cadherin and MMP9) in co-cultured MCF-7 and
MDA-MB-468 cells. Co-cultured CD36-expressing cells had upre-
gulated expression of the EMT markers Twist, Snail, and
N-cadherin compared, to the mock-CD36 cells (Fig. 2A). Western
blot analysis of EMT markers showed upregulated protein
expression of vimentin and ZEB1, with decreased E-cadherin
expression, in co-cultured cells (Fig. 2B). Immunofluorescence
images showed increased vimentin staining and decreased
E-cadherin staining in CD36 expression and co-cultured cells
(Fig. 2C). We used the TCGA breast cancer cohort to interrogate
the correlation between increased CD36 expression and EMT
markers in clinical breast cancer patients. We obtained EMT scores,
as described by Nath et al.15 (Supplementary Fig. 2A, B). The
correlation matrix for CD36 and EMT markers revealed a strong
positive correlation between increased CD36 expression and
mesenchymal markers expression (Fig. 2D and Supplementary Fig.
3A, B) and a strong negative correlation between increased CD36
expression and epithelial markers expression (Fig. 2D and
Supplementary Fig. 3A, B).
Since EMT emergence is strongly linked to stem-cell trait
development17, these findings indicate the potential role of
CD36 in stemness; hence, we investigated the influence of CD36
expression on the emergence of stem cell traits, following direct
co-culturing. Co-cultured mock-CD36 and CD36 expression MCF-
7 and MDA-MB-468 cells had significantly increased mRNA levels
of the stem cell markers CD44 and Oct4 (Fig. 2E). CD36
knockouts significantly decreased the expression of stem-cell
markers (Fig. 2E). Co-cultured cells also showed upregulated
protein levels of the stemness markers CD44, CD133 and ALDH
(Fig. 2F). Co-cultured mock-CD36, CD36 expression and CD36-
knockout cells were sorted, using fluorescence-activated cell
sorting (FACS), to determine CD36-positive (CD36+) only, CD44-
positive (CD44+) only and CD36/CD44-positive (CD36+/CD44+)
cell populations. Expression of stem-cell-like traits occurred only
in a subpopulation of co-cultured cells. In mock-CD36 cells, the
CD36+/CD44+ cell population was significantly fewer (Fig. 2G, H),
compared to the co-cultured mock-CD36 and CD36 expression
cells. The CD36+/CD44+ cell population increased significantly
(Fig. 2G, H). However, the CD36+/CD44+ cell population in the
co-cultured knockout-CD36 cells significantly decreased (Fig. 2G,
H). These results indicate that the emergence of stem-cell-like
traits in breast cancer cells is influenced in part by the
adipocytes, and upregulated CD36 expression enhances the
emergence of the CD36+/CD44+ cell population. Together, these
results indicate a role of CD36 in adipocyte-induced EMT and
stemness. Genetic ablation of CD36 inhibits expression of EMT
and stemness markers.
Genetic ablation of CD36 inhibits adipocyte-induced tumour
growth and tumoursphere formation
The role of CD36 in promoting adipocyte-induced EMT and
stemness indicates a direct role in adipocyte-induced breast
cancer cells aggressiveness. Hence, we determined if the genetic
ablation of CD36 limits adipocyte-induced proliferation, migration,
invasion, and tumorigenesis. Co-cultured CD36-knockout cells had
significantly decreased proliferative, migratory, and invasive
characteristics (Fig. 3A–E). We also examined the effect of CD36
on breast cancer cell motility. Co-cultured CD36-knockout cells
had significantly decreased motility (Supplementary Fig. 3C, D).
Co-cultured mock-CD36 and CD36 expression cells formed more
spheroids, compared with the control group (Fig. 3F, G). CD36-
knockout cells formed inconspicuous and fewer spheroids
(Fig. 3F). Similar findings were observed in the mock-CD36 and
CD36-knockout cells via anchorage formation assay (Fig. 3H, I).
Collectively, these results indicate that CD36 upregulation
enhances the proliferative, migratory, and invasive capabilities of
breast cancer in adipocyte-breast cancer cell interaction.
CD36 induces stemness via activation of the STAT3 signalling
axis
To identify signalling pathways activated, following co-culturing,
and potentially involved in CD36-dependent induction of EMT and
Fig. 1 CD36 is key in adipocyte-released fatty acid import into breast cancer cells. A, B Expression of CD36 was examined by qRT-PCR (a)
and western blot (b) in breast cancer cell lines with different molecular characteristics. C Representative IHC images for CD36 expression in
breast tissues with/without adipocyte infiltration, showing percentage of tissues with weak, medium and strong CD36 staining/adipocyte
infiltration. D Representative images of Oil Red O stained MCF-7 and MDA-MB-468 cells following co-culture with differentiated human
adipocytes. E Quantitative estimation of the rate of fatty acid accumulation in MCF-7 and MDA-MB-468 breast cancer cells at specific time
points (0, 6, 12, 24, 36, 48, 60 and 72 h) following co-culture. F Quantification of intracellular glycerol content in MCF-7 and MDA-MB-468
cultured with/without adipocytes for 48 h. G Quantification of intracellular triglycerol content in MCF-7 and MDA-MB-468 cultured with/
without adipocytes for 48 h. H Comparison between CD36 and SLC27A6 mRNA expression in MCF-7 and MDA-MB-468 cells cultured with/
without adipocyte CM treated with/without the CD36 inhibitor; Sulfosuccinimidyl oleate (SSO). I Quantitative estimation of accumulated fatty
acid following Oil Red O staining in MCF-7 and MDA-MB-468 co-cultured with/without SSO. Relative mRNA expression was normalised to
GAPDH experimental results are representative of three independent experiments. (qRT-PCR data represent mean ± SEM., ***p < 0.001; **p <
0.01; *p < 0.05, n= 3, quantification data indicate mean ± SD; ***p < 0,001; **p < 0.01; *p < 0.05).
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stemness, we determined the levels of various oncogenic pathway
proteins in adipocyte co-cultured breast cancer cells, with
abrogated CD36 activity, by western blotting (Fig. 4A). The PI3K/
AKT, ERK1/2 and STAT3 signalling pathways were activated in
MCF-7 cells and PI3K/AKT, ERK1/2, p38-MAPK and STAT3 signalling
pathways in MDA-MB-468 cells, with increased expression of
phosphorylated forms (Fig. 4A). To identify pathways directly
linked to CD36 activity, we focused on pathways activated in co-
cultured CD36 expression cells and repressed in CD36-knockout
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increased in the CD36-expressing cells and decreased, with
repressed CD36 activity (Fig. 4A).
To validate the direct involvement of the identified pathways
in CD36-dependent effects, we inhibited ERK1/2 and STAT3
using the selective STAT3 (S3I-201) and ERK1/2 (U0126) inhibitors
and determined their effect on CD36 expression and/or activity
following indirect co-culture. CD36, CD44, pSTAT3 and pERK1/2
protein levels increased in cells cultured in adipocyte-
conditioned media, without S3I-201 or U0126, and inhibiting
the pathways decreased CD36 and CD44 expressions (Fig. 4B).
However, inhibiting STAT3 activity had a more significant
decrease on CD36 protein levels, compared to ERK1/2 inhibition
(Fig. 4B and Supplementary Fig. 4A–D). Cell signalling activity of
CD36 is speculated to be mediated by the Tyr-468 and Cys-464
residues at the C-terminus, which interact with Src-protein
tyrosine kinases13. Hence, we determined if CD36-induced STAT3
or ERK1/2 activity involves direct interaction of CD36 with the
signalling molecules. GST-pull-down assay for STAT3, pSTAT3
(Y705), ERK1/2 and pERK1/2 (Thr202/Tyr204) showed a direct
interaction between CD36, STAT3 and pSTAT3 in both MCF-7 and
MDA-MB-468 cells (Fig. 4C). Expectedly, CD36 did not show any
direct interaction with ERK1/2 and pERK1/2 since their activation
usually involves intermediates that do not directly interact with
transmembrane receptors, unlike STAT3, which directly interacts
with transmembrane receptors and translocate to the nucleus
once phosphorylated (Fig. 4C).
We further evaluated the potential role of the STAT3 and
ERK1/2 signalling axis in the emergence of CD36/CD44+ cells.
We cultured mock-CD36 and CD36 expression cells, with
adipocyte-conditioned media and S3I-201 or U0126, for 48 h,
subjected them to flow cytometry, and the CD36/CD44+ cell
population determined. S3I-201 treatment decreased the CD36/
CD44+ cell population in the mock-CD36 and CD36 expression
cells (Fig. 4D). Both STAT3 and ERK1/2 inhibition decreased the
CD36/CD44+ cell population in the mock-CD36 and CD36
expression cells (Fig. 4D). However, STAT3 inhibition produced
a greater decrease in CD36 protein expression and fewer CD36/
CD44+ cell population compared to ERK1/2 inhibition. Alto-
gether, these results indicate that STAT3 and ERK1/2 inhibition
decrease CD36 expression in co-cultured breast cancer cells.
STAT3 inhibition have a greater effect on CD36 expression and
the emergence of stem cell traits.
Phosphorylated STAT3 binds to the CD36 promoter and
regulates CD36 expression
Since STAT3 inhibition decreases CD36 protein expression, we
determined if STAT3 regulates CD36 transcriptional expression.
STAT3 phosphorylation and activation allow binding to the STAT
consensus binding sequences (GAS motif), with the sequence TT-
(A/C)-NNNNA-(A/G) and activate the transcription of their target
genes. We located six unique STAT3 consensus sequences within
the CD36 promoter before the putative start site (Fig. 5A). The
CD36 promoter also contains two distinct interferon-sensitive
response elements (AGTTTCNNTTTCN -(C/T)), which are binding
sites for various STAT proteins involved in gene activation
(Fig. 5A). To determine if the identified binding sites regulate
CD36 expression, we designed Chip-primers spanning the six
identified STAT3 consensus sequences (Supplementary Table 3)
and performed a chip assay. Co-cultured mock-CD36 and CD36
expression MCF-7 and MDA-MB-468 cells had significant enrich-
ment with primers 3 and 5, but marginal for primer 6.
Enrichment for primers 3, 5 and 6 decreased in the CD36-
knockout cells (Fig. 5B, C).
The presence of unique STAT3 GAS-element in the CD36
promoter indicates the potential for STAT3 to regulate CD36
expression. To test this, the SIE site in the pGL4.4 (luc2P/SIE/hygro)
plasmid was replaced, with 5 repeating STAT3 promoter sequence
#3 (wildtype -construct 1), #5 (wildtype construct 2) and mutant
forms (Fig. 5D). We transfected MCF-7 and MDA-MB-468 cells, with
the wildtype, and mutant STAT3 promoter constructs (1 and 2),
stimulated them with 50 ng IL-6, and determined the luciferase
activity of both constructs. Cells transfected, with wildtype
constructs (1 and 2), had significantly increased luciferase activity
after IL-6 stimulation, compared to cells transfected with the
mutant constructs (1 and 2) (Fig. 5E, F). Thus, the identified STAT3
consensus sequences (3 and 5) in the CD36 promoter can
stimulate luciferase gene expression. These results indicate that
pSTAT3 induces CD36 transcription by binding to its putative
consensus sequence in the CD36 promoter.
CD36 regulates metabolic reprogramming towards fatty acid
oxidation
To determine if increased CD36 expression results in metabolic
changes, we used the GO-lipid metabolic process gene list
present in the molecular signature database (MSigDB) to
generate a correlation matrix for increased CD36 expression in
the TCGA breast cancer patient dataset. We identified 26 key
genes, with expression positively correlated, with increased CD36
expression (Fig. 6A and Supplementary Fig. 5A). Based on the
ascribed gene function, the identified genes were put into four
groups: Lipid and fatty acid transport (AQP7P1, AQP7P3, AQP7,
FABP4 and LDL), fatty acid metabolism (ACSM3, EHHADH, ACSM5,
ACADL, ADIPOQ, CYP7A1, ACSBG1 and SCD5), drug resistance
(ABCB11, ABCB4, ABCG2, ABCA6, ABCC9 and ABCD2) and others
(WSCD1, WSCD2, MMP19 and SORBS1) (Fig. 6B). Of note is the
increased expression of AQP7 (aquaporin 7) and its isoforms
(AQP7P1 and AQP7P3), which export glycerol from fatty acid
metabolism; FABP4, which binds and shuttles fatty acids into cells
and subcellular locations for metabolism; Acyl-CoA synthetases
(ACSM3, ACSM5), which activate fatty acids in the first step of their
metabolism; and acyl-CoA dehydrogenase long-chain (ACADL),
which catalyses the first step of mitochondrial fatty acid beta-
oxidation (Fig. 6B). The data suggest a causal relation between
increased CD36 expression and cell energy reprogramming
towards fatty acid metabolism, with increased expression of
enzymes and transporters involved in FAO.
To validate the functional effect of CD36-induced fatty acid
uptake on enhanced FAO and metabolic reprogramming in breast
Fig. 2 Genetic ablation of CD36 attenuates adipocyte-induced EMT and stemness in breast cancer cells. A Quantitative real-time-PCR (qRT-
PCR) comparing the expression of EMT-TFs (TWIST1 and SNAIL) and EMT-related genes (MMP9, N-cadherin and E-cadherin) in MCF-7 and
MDA-MB-468 cells co-cultured with adipocytes. B Expression of CD36 and EMT related markers (vimentin, ZEB1 and e-cadherin) in cells
following CD36 knockout and co-culture with adipocytes was analysed by western blotting. C Representative immunofluorescence images of
vimentin (red) and e-cadherin (green) in cells. Nucleus was stained with DAPI. D Correlation matrix showing the association between CD36
and EMT-related markers. E qRT-PCR comparing the expression of stem cell markers (CD44, CD133, Oct4 and Sox2) in MCF-7 and MDA-MB-468
cells co-cultured with adipocytes. F Expression of CD36 and stem cell markers (CD44, CD133 and ALDH) in cells following CD36 knockout and
co-culture with adipocytes was analysed by western blotting. G MCF-7 and MDA-MB-468 cell populations was sorted by flow cytometry for
CD36+/CD44+ cells after co-culture with adipocytes. H Percentage of cells with positive CD36/CD44 expression in MCF-7 and MDA-MB-468
after co-culture with adipocytes. (qRT-PCR data represent mean ± SEM., ***p < 0,001; **p < 0.01; *p < 0.05, n= 3. Quantitative data indicate
mean ± SD; ***p < 0,001; **p < 0.01; *p < 0.05) (I, J).
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cancer cells, we assessed the metabolic changes following
culturing with adipocyte-conditioned media, using the Seahorse
XF24 analyser. We determined the energy phenotype of co-
cultured mock-CD36, CD36 expression and CD36-knockout cells.
We found that CD36 abrogation induced a quiescent energy state
in the cells, with low glycolytic and metabolic respiratory
pathways (Supplementary Fig. 5B). Co-cultured mock-CD36 and
CD36-expressing cells assumed an energetic phenotype, indicat-
ing enhanced mitochondrial respiration (Supplementary Fig. 5B).
Thus, breast cancer cells alter their metabolic programmes,
J. Gyamfi et al.
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with increased mitochondrial respiration, to meet their energy
needs, with the available fatty acids. CD36 is key for this energy
shift in breast cancer cells. CD36 knockout inhibits mitochondrial
respiration and shifts the cell’s energy phenotype towards a
quiescent state.
To investigate if the enhanced mitochondrial function in co-
cultured cells is FAO-dependent, we measured the oxygen
consumption rate (OCR) using the seahorse FAO assay kit. Basal
OCR was significantly increased in co-cultured mock-CD36 and
CD36-expressing cells (Fig. 5C, D). Treatment with carnitine-
palmitoyltransferease-1 (CPT1) inhibitor, etomoxir (ETO) showed a
sharp OCR decrease in the co-cultured mock-CD36 and CD36
expression cells (Fig. 5C, D and Supplementary Fig. 5E, F). These
findings indicate enhanced FAO in co-cultured mock-CD36 and
CD36 expression cells. We determined if the presence of excess
FFA acids supplied by cancer-associated adipocytes induced a
metabolic shift towards fatty acid fuel dependency using the
seahorse mito-fuel flex assay. In mock-CD36 cells co-cultured with
adipocytes, dependency on fatty acids doubled in comparison to
control cells (Fig. 6E). While in CD36 knockouts dependency on
fatty acid decreased to <26% (Fig. 6E). Co-cultured CD36
expression cells had over 70% dependency on fatty acids (Fig. 6E).
Mechanistically, overexpression of CD36 resulted in activation of
the PPAR signalling axis, with increase PPARα and PPARγ
expression (Fig. 6F, H). The shift towards fatty acid metabolism
occurs with an increase protein expression of pAMPK, and ATGL,
proteins that mediate fatty acid metabolism (Fig. 6G and
Supplementary Fig. 6). While knockout of CD36 cells had increased
protein expression of FASN, required for fatty acid synthesis
(Fig. 6G and Supplementary Figs. 5 and 6). Taken together, these
findings suggest a metabolic remodelling in breast cancer cells, in
the presence of adipocytes. With increased expression of CD36
and proteins involved in fatty acid metabolism, which potentiates
the shifts towards fatty acid metabolism, with enhanced
mitochondrial respiration.
CD36 directly interacts with FABP4 to mediate fatty acid
localisation and metabolism
Based on our earlier results indicating a close association between
CD36 and FABP4 (Fig. 6A), we compared their expression in the
mock-CD36, CD36 expression and CD36-knockout cells, with/
without adipocytes by qRT-PCR. Interestingly, both CD36 and
FABP4 expressions increased in co-cultured cells (Fig. 7A). Next, we
determined the correlation between increased CD36 expression
and the various FABP genes (FABP1, FABP2, FABP3, FABP4, FABP5
and FABP6) in the TCGA breast cancer cohort. A strong positive
correlation existed between CD36 and FABP4, compared to other
FABP forms (Supplementary Fig. 7B). To further explore this
association, we combined the GO-fatty acid transmembrane
transport, activity and binding activity dataset and generated a
large dataset named the CD36-fatty acid partner dataset
(Supplementary Fig. 7C). Using the TCGA database, we screened
16 tumour cohorts for the top 10 genes that positively correlated
with increased CD36 expression. Interestingly, in the clinical
datasets explored, FABP4 was the most common protein
correlating with increased CD36 expression in 15 out of the 16
tumour types assessed (Supplementary Fig. 7C, D).
We hypothesised that the significant correlation between CD36
and FABP4 expression depended on their direct interaction to
regulate fatty acid import and metabolism. To interrogate this, we
performed an amino acid sequence alignment for CD36 and FABP4
and observed ten highly similar amino acid sequences and
possible interacting motifs (Supplementary Fig. 7A). Non-
denaturing immunoprecipitation assay revealed three distinct
bands, indicating a possible interaction between CD36 and FABP4
and other proteins (Fig. 7B). Denaturing immunoprecipitation
showed that CD36 specifically immunoprecipitated FABP4 (Fig. 7B).
To validate this observation, we cloned the CD36 gene into the
pGEX-4T-3 plasmid, followed by a pull-down assay, and blotting
with an anti-FABP4 antibody. The results showed increased FABP4
pull-down in co-cultured CD36-expressing cells (Fig. 7C). We next
examined the subcellular localisation of CD36 and FABP4. The
cytoplasmic fraction had significantly increased CD36 and FABP4
protein levels in the co-cultured mock-CD36 and CD36-expression
cells (Fig. 7D). Taken together, these results indicate a direct
interaction between CD36 and FABP4 in the cytoplasmic region
may regulate fatty acid import and metabolism. We can speculate
from these findings that CD36 act as the transmembrane fatty acid
importer, specifically involved in transmembrane fatty acid import
FABP4 binds to fatty acids and interact with CD36 to import and
shuttle them to various subcellular locations.
Chemical inhibition of CD36 and FABP4 induces apoptosis in
breast cancer cells and reduces primary tumour growth in
xenograft mouse model
Various studies have reported the potential for CD36 and FABP4
to be targeted for therapy in different cancers, indicating that
targeting either CD36, FABP4 or both may provide therapeutic
opportunities. The observation that these proteins directly
interact to regulate lipid/FFA metabolism creates an opportunity
to inhibit both proteins for an enhanced effect. Thus, CD36 was
inhibited, with SSO, and FABP4, with BMS309403 (Supplemen-
tary Fig. 8A), and their effects on breast cancer cells determined
(Fig. 8A–C). Inhibiting either at recommended concentrations did
not significantly decrease MCF-7 and MDA-MB-468 cell viability
over 72 h (Supplementary Fig. 8B). However, inhibiting both
CD36 and FABP4 significantly decreased the breast cancer cell
viability over 72 h (Supplementary Fig. 8B). Similarly, CD36 and
FABP4 inhibition significantly decreased the proliferative, migra-
tory, and invasive abilities of breast cancer cells (Fig. 8A–C and
Supplementary Fig. 8).
To understand how treatment with either SSO or BMS-309403
decreased proliferation, migration and invasion capabilities of
breast cancer cells while still maintaining cell viability we assessed
the expression levels of markers associated with cell senescence
(DEC1, DcR1 and DcR2) and markers associated with cell cycle
arrest (p21cip1, p16 and p53). In both MCF-7 and MDA-MB-468,
there were unique and significant changes in the expression
of cell senescence and cell cycle arrest markers (Fig. 8D, F).
These findings indicate that inhibition of either CD36 with SSO or
Fig. 3 Genetic ablation of CD36 inhibits adipocyte-induced tumour growth and tumoursphere formation. A Evaluation of effect of CD36
ablation on proliferation of MCF-7 and MDA-MB-468 breast cancer cells co-cultured with adipocytes for 48 h. Representative images of MCF-
7 (B) and MDA-MB-468 (D) migration and invasion (×200 magnification) after co-culture with differentiated human adipocytes. Quantitative
analysis of migration and invasion cell numbers of MCF-7 (C) and MDA-MB-468 (E) breast cancer cells following CD36 ablation and co-culture
with adipocytes. F, G Evaluation of the tumour formation capabilities of CD36 expression MCF-7 and MDA-MB-468 cells co-cultured with/
without adipocytes. Representative images of spheroid formation ability of MCF-7 and MDA-MB-468 cells (F). Quantitative analysis of
number of spheroids formed by MCF-7 and MDA-MB-468 cells (G). H Representative images of colony formation ability of CD36 expression
MCF-7 and MDA-MB-468 breast cancer cells after co-culture with/without adipocytes. I Quantitative analysis of the number of colonies
formed by MCF-7 and MDA-MB-468 cells. All results are representative of three independent experiments. (Data indicate mean ± SD; ***p <
0.001; **p < 0.01; *p < 0.05).
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Fig. 4 Upregulation of CD36 occurs with activation of the ERK1/2 and STAT3 signalling pathway. A Expression of key signalling
pathway targets (PI3K/AKT, TGF-β/SMAD, MAPK/ERK1/2, p38 MAPK and JAK/STAT3) involved in tumour progression in cells following
overexpression and genetic ablation of CD36 was analysed by western blotting. B Expression of CD36, CD44, ERK1/2, pERK1/2, STAT3
and pSTAT3 in MCF-7 and MDA-MB-468 cell following treatment with the ERK1/2 inhibitor (UO126) and STAT3 inhibitors (S3I-201),
analysed by western blotting. C Representative western bolt of GST pull-down assay indicating CD36 directly interacts with STAT3.
D Percentage of cells with CD36+/CD44+ expression in MCF-7 and MDA-MB-468 after co-culture with adipocytes and treated with/
without U0126 and S3I-201. Experimental results are representative of three independent experiments. (Data indicate mean ± SD;
***p < 0,001; **p < 0.01; *p < 0.05).
J. Gyamfi et al.
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FABP4 with BMS-309403 induced incomplete senescence in MCF-
7 and MDA-MB-468 cells with changes in the expression of cell
senescence markers and cell cycle arrest markers (Fig. 8D, F).
Combined SSO and BMS309403 treated cells treated showed
apoptotic characteristics (Supplementary Fig. 8E). Hence, we
determined the protein expression levels of apoptosis-associated
markers. In both cells, combining SSO and BMS309403 decreased
the expression of the apoptosis markers BCL-xL, with an increase
in the apoptosis markers CL-Cas3 and PUMA (Fig. 8E). Assessment
of the number of apoptotic cells by annexin V/PI assay showed
that SSO and BMS309403 treatment increased the proportion






Fig. 5 STAT3 binds to the CD36 promoter and regulate CD36 expression. A Schematic representation of the location of identified STAT3
GAS- and ISRE-elements in the CD36 promoter. B Chromatin immunoprecipitation (ChIP) assay on the promoter of CD36, showing pSTAT3
bound to predicted CD36-binding sites. GAPDH is shown as a negative control. C qRT-PCR of ChIP assay in MCF-7 and MDA-MB-468 cells.
CD36 promoter occupancy by STAT3 primers 3, 5 and 6 is increased with adipocytes co-culture but is strongly reduced in CD36 ablated cells.
D A schematic diagram of the STAT3 consensus sequence luciferase constructs 1 and 2 and mutant constructs 1 and 2. E, F Luciferase
constructs were stimulated with IL-6 (50 ng) to induce luciferase activity. Relative luciferase activity was normalised against a non-inducible
luciferase construct. All results are representative of three independent experiments. Relative mRNA expression was normalised to GAPDH
experimental results are representative of three independent experiments. (qRT-PCR data indicate mean ± SEM; ***p < 0,001; **p < 0.01; *p <
0.05. Relative luciferase activity data indicate mean ± SD; ***p < 0,001; **p < 0.01; *p < 0.05).
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These findings indicate that chemical inhibition of CD36 and FABP4
functions results in significant apoptosis with distinct morphological
phenotypes in the breast cancer cells (Supplementary Fig. 8E). SSO
treatment resulted in cell clustering, with significant lipid accumula-
tion. Treatment with both SSO and BMS309403 resulted in
clustering of cells and increased lipid content, indicating an inability
to metabolise lipids resulting potentially in lipotoxicity-induced
apoptosis (Supplementary Fig. 8E–I).
We further verified the potential for CD36 and FABP4 inhibitors
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through in vivo xenograft nude mice models. To enable
physiological visualisation of tumour growth breast cancer cells
were first transfected with a luciferase reporter before engrafting.
Tumours were generated in female Balb/C nude mice and mice
were randomly assigned into four groups of five mice each. Group
1 (G1) were treated daily with PBS (vehicle), group 2 (G2) were
treated daily with 15mg/kg dose of the FABP4 inhibitor;
BMS309403, group 3 (G3) were treated with 40mg/kg with the
CD36 inhibitor (SSO) twice a week by intraperitoneal injections
and group 4 (G4) were treated with a combination of BMS309403
and SSO. Although the weight of mice in the control group were
slightly higher than all other groups, mice weight were not
significantly different between experimental groups over the
study period (Fig. 8H). We demonstrated that treatment with
either BMS309403 or SSO alone decreased the rate of tumour
formation and the combination of BMS309403 and SSO signifi-
cantly decreased the rate of tumour formation (Fig. 8I). Measure-
ments of tumour volume (Fig. 8I) and luciferase activity (Fig. 8J, K)
revealed an initial slow response to treatment options. However,
after 31 days of treatment we observe that therapy profoundly
limited tumour growth. We did not observe a significant
difference in tumour growth in groups that received treatment
options of either BMS309403 alone, SSO alone or combination of
BMS309403 and SSO. However, compared to vehicle group we
observe a significant decrease in tumour growth in mice that
received treatment (Fig. 8K). Taking all together these findings
indicate that inhibiting both CD36 and FABP4 induces significant
accumulation of unmetabolized lipid, resulting in apoptosis in
breast cancer cells and chemical inhibitors of CD36 and FABP4
effectively reduces tumour growth in vivo.
DISCUSSION
The oncogenic properties of CD36 have been reported in breast,
ovarian and hepatocellular carcinomas14,15,18. Contrary to decreas-
ing breast cancer cell proliferation and aggressiveness, CD36
expression reportedly also has a tumour suppressive role. In
colorectal cancer, a progressive decrease in CD36 expression
reportedly leads to tumour progression from adenomas to
carcinoma, with CD36 loss enhancing prognosis19. These contrast-
ing reports on CD36 function may indicate its context-specific role
in cancer. Thus, we extensively explored the role of CD36 in
adipocyte-breast cancer cell interaction. In this study, we found that
CD36 expression increased, following co-culturing breast cancer
cells with hADS, and in the clinical data of breast cancer patients.
IHC staining showed that a high proportion of breast tumours, with
adipose tissue infiltration, have moderate to high CD36 expression.
The observation of an increased CD36 expression and tumour
invasiveness is consistent with finding by Zaoui et al.20. This result is
consistent with studies by Diret et al., Manabe et al. and Fletcher
et al., where CD36 expression was increased in tumour regions
closely associated with adipose tissues1,21,22. Consistent with the
context-specific CD36 expression, co-culturing breast cancer cells of
distinct molecular phenotypes, with differentiated hADS, increased
CD36 expression. Thus, upregulation of CD36 in response to
exogenous fatty acids may be an adaption mechanism enhanced in
tumourigenic breast cells.
The adipose tissue population in close/direct contact with
cancer cells are commonly called cancer-associated adipocytes
(CAAs). They have distinct characteristics from adipose/adipocytes
not associated with cancer cells. Breast cancer tissue-infiltrated
adipose tissues with breast cancer cells infiltration have signifi-
cantly decreased lipid droplet size. Notably, CAAs have signifi-
cantly increased expression of IL-6 and leptin. Increased CAA-
released IL-6 and leptin are essential tumour growth enhan-
cers20,23–25. Wang et al. recently reported that human breast
adipocyte-derived leptin activates the JAK/STAT3 pathway and
influences breast cancer stem cell renewal and chemoresistance6.
These findings imply that adipocyte-cancer cell interaction
increases lipolysis and resulted in an assumption of an inflamma-
tory state. The inflamed adipocytes secrete various adipocytokines
notably IL-6 and leptin that enhance carcinoma growth.
Gain- and loss-of-function studies, with stable CD36 knockouts
and CD36 expression cells, showed that co-cultured breast cancer
cells have phenotypic changes characteristic of EMT, i.e.,
dispersed, and elongated. Increased CD36 expression in hepato-
cellular carcinomas reportedly induces EMT and elevates FFA
levels. Our results indicate that the CD36-mediated fatty acid
uptake potentiates the expression of EMT transcription factors
TWIST and SNAIL. Genetic ablation of CD36 inhibits fatty acid
import and EMT induction, with decreased EMT-TFs and EMT-
related marker expression. The correlation between increased
CD36 expression and EMT markers was also present in the breast
cancer cohorts. Increased CD36 expression increased the expres-
sion of the mesenchymal markers ZEB1, ZEB2 and FN1 and
decreased expression of epithelial cell markers, CDH1, TJP3 and
MUC1. These findings imply that in the adipocyte-rich micro-
environment, increased CD36 expression enhances FFA uptake
and paracrine signalling involving adipocytokines (IL-6, leptin and
TGF-β) potentiates the emergence of EMT in breast cancer cells.
The emergence of EMT indicates enhanced plasticity of cancer
cells, which is a key contributor to the development of therapeutic
resistance17,26.
CD36 induces EMT via the activation of oncogenic signalling
pathways. Our results show that the STAT3 and ERK1/2 signalling
pathways are activated, with upregulated CD36 and co-
culturing. Abrogation of CD36 downregulates these signalling
pathways. Activation of the STAT3 pathway is linked to both
Fig. 6 CD36 regulates metabolic reprogramming towards fatty acid oxidation. A Correlation matrix heatmap showing the association
between CD36 mRNA expression z-scores (TCGA breast cancer dataset) with genes related to fatty acid metabolic activity. B Classification of
positively correlated genes into groups based on their associated functions. C XFe24 Seahorse FAO assay in MCF-7 and MDA-MB-468 cells
with/without CD36 ablation cultured with/without adipocytes in real time under basal conditions and in response to mitochondrial CPT1
inhibitor (Etomoxir). D The FAO OCR rate of MCF-7 and MDA-MB-468 cells with/without CD36 ablation cultured with/without adipocytes (Data
indicate mean of three time points ± SD; p values were calculated using Student’s t test, ***p < 0,001; **p < 0.01; *p < 0.05). E OCR was
measured during the Seahorse XF Mito-Fuel Flex assay. The percentage of dependence on fatty acids was calculated by quantifying the
change in basal OCR after fatty acid oxidation was blocked using 4 μM etomoxir and divided by the total change in OCR from baseline after
combined inhibition of fatty acid, glutamine and pyruvate oxidation using 4 μM etomoxir, 3 μM BPTES and 2 μM UK5099, respectively. Fatty
acid fuel flexibility was calculated by measuring the change in sensitivity to etomoxir’s inhibition of OCR after blockade of glutamine and
glucose oxidation and represents the ability of MCF-7 and MDA-MB-468 cells to increase oxidation of fatty acid when glutamine and pyruvate
utilisation is precluded. F Relative luciferase activity in MCF-7 and MDA-MB-468 cells transfected with PPAR luciferase reporter plasmid and
cultured with/without adipocytes. Luciferase activity was normalised against a non-inducible luciferase construct. G Expression of AMPK,
pAMPK, ACC, pACC, ATGL and FASN in MCF-7 and MDA-MB-468 cells with/without CD36 genetic ablation and co-cultured with adipocytes
analysed by western blotting. H Expression of PPARα, PPARβ and PPARγ in MCF-7 and MDA-MB-468 cells with/without CD36 genetic ablation
and co-cultured with adipocytes analysed by western blotting. Relative mRNA expression was normalised to GAPDH. Experimental results are
representative of three independent experiments. (Data indicate mean ± SEM.; ***p < 0,001; **p < 0.01; *p < 0.05).
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Fig. 7 CD36 directly interacts with FABP4 to mediate fatty acid metabolism. A Quantitative real-time-PCR (qRT-PCR) comparing the
expression of CD36 and FABP4 in MCF-7 and MDA-MB-468 co-cultured with adipocytes. B Immunoprecipitation with CD36 antibody revealed
that FABP4 binds to CD36 in MCF-7 and MDA-MB-468 cell lines. C GST-tagged CD36 was immobilised to agarose beads after mixing with
breast cancer cell lysate, eluted proteins were blotted with FABP4 antibody. Validation of GST-CD36 tagged protein by Coomassie blue
staining. D Representative western blot of FABP4. FABP4 directly interacts with CD36. E Total nuclear and cytoplasmic levels of CD36 and
FABP4 in MCF-7 and MDA-MB-468 cells cultured with/without adipocytes was analysed by western blot, α-lamin and β-actin were used as
loading controls for nuclear and cytoplasmic fraction respectively. Relative mRNA expression was normalised to GAPDH. Experimental results
are representative of three independent experiments. (qRT-PCR data are mean ± SEM, ***p < 0,001; **p < 0.01; *p < 0.05).
J. Gyamfi et al.
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adipocyte-induced EMT and stemness in breast cancer cells.
Adipocyte-induced ERK1/2 pathways have also been reported in
ERα positive breast cancer cells18. The STAT3 pathway regulates
genes mediating tumour proliferation (cyclin D1 and cyclin B),
invasion (E-cadherin and FAK) and metastasis (MMP9 and
TWIST)27. Thus, CD36-induced activation of the ERK1/2 and
STAT3 signalling pathways in the adipocyte environment may
account for the enhanced proliferation, migration and invasion
of breast cancer cells.
Fatty acid import drives metabolic reprogramming, which shifts
towards FAO as opposed to enhanced glycolysis in cancer cells28.
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increased expression of lipid transport receptors (LDL) and FABP4.
The increased FABP4 expression in this study corroborates
several studies, which have linked increased FABP4 expression
to poor prognosis in several cancers, without any specific link to
CD3629–31. We believe the correlation between CD36 and FABP4
maintains homoeostasis in the rate of fatty acid import and
metabolism, ensuring that imported fatty acids are effectively
shuttled to subcellular locations (mitochondria and peroxisomes).
Importantly, several enzymes involved in FAO were also upregu-
lated, with upregulated CD36 and fatty acid import. The observed
increase in the expression of drug metabolism genes (ABCB11,
ABCB4, ABCG2, ABCA6, ABCC9 and ABCD2), with increased CD36
expression, remain unexploited. This observation has been
previously highlighted by Iwamoto et al., who reported that the
lipid-dependent metabolic reprogramming resulted in angiogenic
drug resistance32. This alteration may account for the reported
chemoresistance observed in breast cancer cell and the adipocyte
co-culture33. However, further studies are required to further
elucidate this relationship.
The association between CD36 and FABP4 expression has been
reported by Zaoui et al. in breast cancer cells20. Interestingly, they
observe that the ability of adipocyte to induce metabolic
reprogramming occurred independent of BMI, menopausal status
and mammary density. Our observation of a correlation between
CD36 and FABP4 in a variety of cancers, and the direct interaction
between CD36 and FABP4 offer a key insight to how adipocyte
induce metabolic reprogramming. The direct interaction between
CD36 and FABP4 reveals that FABP4 may mediate binding and
intracellular shuttling of imported fatty acids for metabolism. We
speculate that in the plasma membrane, FABP4 binds directly to
CD36 and mediates fatty acid import, and in the cytosol, it shuttles
fatty acid to the mitochondria and peroxisomes. This observation
is particularly striking since several studies have investigate CD36
and FABP4 functions, independently. The direct interaction and
interplay between these in regulating fatty acid import and
metabolism requires studies that focus on how inhibiting either
CD36 or FABP4 influences the other and fatty acid metabolism.
This study is presently limited by the absence of an experimental
in vivo model for validation; however, using human-differentiated
adipocytes, compared to murine adipocytes, offers greater value
and validation of the effect of SSO and BMS309403 in xenograft
model offers valuable insight.
In conclusion, CD36 is a key player in adipocyte-breast cancer
cell interaction. The function of CD36 is context-specific, with
increased expression in adipocyte co-cultures. Increased CD36
expression activates the STAT3 signalling pathway required for
adipocyte-induced EMT and stemness. STAT3 activation creates a
feedforward loop for the transcriptional regulation of CD36
expression. FABP4 is a key partner for CD36. Their direct
interaction regulates fatty acid import. Combined inhibition of
CD36 and FABP4 may be an efficient approach, compared to
independent inhibition of each. Our use of human derived
adipocytes compared to the widely use murine adipocyte is an
advantage. Validation of our findings in patient tissues by IHC and
in patients’ data in the TCGA provides valuable insights. This study
is presently limited by the absence of a suitable in vivo model to
study how adipocyte influence breast cancer progression.
METHODS
Study design
Collection of human tissues for primary adipocyte isolation and human
breast cancer samples were obtained from consenting patients in
accordance with guidelines and regulations approved by the Institutional
Review Board of Severance Hospital, Yonsei University Health System (4-
2014-0054).
Cell culture and treatments
Breast cancer cells line MCF10A, MCF-7, MDA-MB-468, BT-483 and
HCC2218 were obtained from American Type Culture Collection (ATCC,
Manassas, VA, USA). Upon thawing and passaging, cells were used until
passage number 20. Mycoplasma testing was done every other month,
using the MycoAlert following manufacturers protocol (Lonza, Cat# LT07-
318). Non-tumorigenic breast epithelial cell MCF10A cultured in DMEM
supplemented with 5% horse serum, 1% penicillin-streptomycin. MDA-MB-
468 and MCF-7 were cultured in DMEM mixed with F12 (DMEM/F12;
Welgene) supplemented with 10% FBS and 1% penicillin-streptomycin. BT-
483 and HCC2218 cells were cultured in RPMI-1640 supplemented with
20% FBS, 1% penicillin-streptomycin. Where required cells were treated
with 200 μM of Sulfo-N-succinimidyl oleate (SSO), 100 μM STAT3 inhibitor
(S3I-201) (Santa Cruz), 60 nM ERK1/2 inhibitor (U0126) (Santa Cruz) and
20 μM BMS-309402 (Millipore).
Differentiation of adipocytes and collection of adipocyte-
conditioned media
Primary adipocytes were isolated from subcutaneous adipose tissues as by-
product of human patients with colon cancer as described by Lee et al.34,35
Isolated primary preadipocytes was maintained and expanded in DMEM,
supplemented with 10% fatal bovine serum (FBS; GibcoTM, Life Technol-
ogies, Carlsbad, CA, USA) and 1% penicillin-streptomycin (GibcoTM).
Differentiation into matured adipocytes was done using adipogenic
differentiation media [DMEM with 5% FBS and 1% Penicillin-
streptomycin supplemented with 0.5 mM isobutylmethylxanthine (Sigma-
Aldrich, St Louis, MO, USA), 1 μM dexamethasone (Sigma-Aldrich), 1 μg/ml
insulin (Sigma-Aldrich), 2 nM T3, 10 μg/ml transferrin, 1 μM rosiglitazone,
33 uM biotin and 17 uM pantothenic acid] for 7 days. Adipogenic
differentiation media was replaced with adipogenic maintenance media
[DMEM with 5% FBS and 1% Penicillin-streptomycin supplemented with
1 μg/ml insulin (Sigma-Aldrich)] and 10 nmol/l dexamethasone (Sigma-
Aldrich) for an additional 7 days. Adipocytes are rinsed with PBS and
replaced with complete media without differentiation factors and used in
direct co-culture. Collection of human tissues for primary adipocyte
isolation was carried out in accordance with guidelines and regulations
approved by the Institutional Review Board of Severance Hospital, Yonsei
University Health System (4-2014-0054), after informed consent was
Fig. 8 Combined inhibition of CD36 and FABP4 induces apoptosis in breast cancer cells. A Proliferation capabilities of breast cancer cells
assessed after treatment with SSO and BMS309403 inhibitors at specific time points (0, 24, 48, 72- and 96-h). Quantitative analysis of migration
(B) and invasion (C) cell numbers of MCF-7 and MDA-MB-468 cells cultured with/without adipocyte CM and treated with/without SSO and
BMS309403. All results are representative of three independent experiments. D qRT-PCR comparing the expression of DEC1, DcR1 and DcR2 in
MCF-7 and MDA-MB-468 cells cultured with/without adipocyte CM and treated with/without SSO and BMS309403t. E qRT-PCR comparing the
expression of p16, p21 and p53 in MCF-7 and MDA-MB-468 cells cultured with/without adipocyte CM and treated with/without SSO and
BMS309403. F Expression of CD36, FABP4, Bax, Bcl-xl, caspase-3, cleaved caspase-3 and PUMA in MCF-7 and MDA-MB-468 cells treated with
SSO and BMS309403 assessed by western blotting. G Evaluation of apoptosis in breast cancer cells treated with SSO and BMS309403 using
Annexin V/PI dual-labelling technique. Quantitative analysis of percentage of MCF-7 and MDA-MB-468 cells undergoing apoptosis.
H Comparison of weight of mice from different treatment groups (Vehicle, FABP4 inhibitor, CD36 inhibitor and CD36+ FABP4 inhibitor) over
time. I Comparison of tumour formed in mice from different treatment groups. Tumour formed in mice receiving treatment where smaller
compared to vehicle group. J Tumour size were determined by measuring the intensity of luciferin by IVIS Lumina XRMS in vivo imaging
system. K Plot of tumour size measurements over time. Results indicate significant inhibition of tumour formation in treatment groups
compared to vehicle group. Relative mRNA expression was normalised to GAPDH. Experimental results are representative of three
independent experiments. (qRT-PCR data indicate mean ± SEM; ***p < 0.001; **p < 0.01; *p < 0.05).
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obtained from patients. Following full differentiation of adipocytes,
maintenance media is replaced with fresh complete media after 48 h,
adipocyte-conditioned media is collected, centrifuged at −4 °C. The
supernatant is collected and stored at −20 °C until used.
Co-culture
Co-culture of adipocytes and breast cancer was done by two methods. The
direct co-culture procedure, adipocytes are differentiated in the bottom
well of the 6-well transwell co-culture system. Breast cancer cells are
subsequently seeded into the transwell inserts and cultured with
adipocytes for the required period. Experiments are conducted by direct
co-culture unless otherwise indicated. In the indirect-co-culture system, cell
culture media of breast cancer cells is replaced with 75% adipocyte-
conditioned media. All experiments requiring chemical treatment are
conducted by the indirect co-culture method.
Oil red O staining/intracellular lipid quantification
Differentiated hADS and co-cultured breast cancer cells was evaluated for
their intracellular lipid content by Oil Red O staining. Cells are fixed with
4% paraformaldehyde for 20min at room temperature (RT), rinsed with
PBS and distilled water and stained for 30min with Oil Red O. Cells are five
times with water and images acquired using the Olympus BX53
microscope (Olympus Optical Co., Tokyo, Japan). Quantification of
intracellular lipid content was performed after stained cells are rinsed
with water and with 60% isopropanol. In total, 100% isopropanol was used
to extract Oil Red O and 200 µl of extracted Oil Red O is transferred into a
96-well plate (in triplicated) and measured spectrophotometrically at
492 nm (Tecan Group limited, Männedorf, Switzerland).
Triglyceride and glycerol content analysis
Intracellular triglyceride in adipocytes and breast cancer cells were
quantified using the Cayman triglyceride colorimetric assay kit (Cayman
chemical, Ann Arbor, USA) following manufacturers instruction. Results
were read spectrophotometrically at 550 nm (Tecan Group limited,
Männedorf, Switzerland). Intracellular glycerol of breast cancer cells and
extracellular glycerol levels from adipocytes was assessed using the
glycerol-free reagent kit (Sigma-Aldrich) following manufacturer’s
instruction.
Proliferation and viability assay
For breast cancer cell proliferation rate, 2500 cells were seeded into a 96-
well plate for overnight. Complete media is replaced with serum free
media and cultured for 12 h. After 12 h, media is replaced with adipocyte
CM or complete media and cell proliferation assessed at 6, 12, 24, 36, 48,
60, 72 and 96 h, all reactions are performed in triplicate. After each time,
10 μl of CCK-8 solution (Dojindo, Kumamoto, Japan) was added to each
well and incubated for 2 h and optical density was measured spectro-
photometrically at 450 nm (Tecan Group limited, Männedorf, Switzerland).
Cell viability after CD36 knockout or treatment with SSO, S31-201, U0126
and BMS-30940 was determined by seeding 2500 cells in 96-well plate, and
cultured for 24 h, after which treatment agent is added at appropriate
concentration and maintained for 72 h. Cell viabilities was evaluated at 6,
12, 24, 36, 48, 60 and 72 h using the EZ-CYTOX cell viability kit (Douzen,
Seoul, Korea). Briefly, 10 μl of EZ-cytox reagent (DoGEN, Kumamoto, Korea)
was added to each well and incubated for 2 h at 37 °C and absorbance
measured at 450 nm spectrophotometrically (Tecan Group limited,
Männedorf, Switzerland).
Colony and spheroid formation assay
For colony formation assay co-cultured and control breast cancer cells
were seeded at 1000 cells per ml in 6-well plates and incubated at 37 °C.
Cells are maintained in complete or adipocyte-conditioned media for
14 days. Cell culture media was changed every 3 days. After day 14, cells
are rinsed with PBS, fixed with acetic acid and methanol (1:3), and stained
with 0.05% crystal violet. Images are captured and number of colonies
formed counted using ImageJ software. For spheroid formation, 2500 co-
cultured and control cells were mixed with DMEM containing 0.35% soft
agar (Difco, Mubai, India) and plated in a six-well plate coated with 0.6%
soft agar. Adipocyte CM or complete media is added to the plate after
every 3 days. After 14 days, the number of spheroids formed in three
random microscopic fields were counted, and the images were captured
using the lionheart FX microscope (BioTek Instruments Inc. Winooski,
VT, USA).
Wound healing, migration and invasion assay
Wound healing assay for co-cultured and control MDA-MB-468 and MCF-
7 cells are seeded at 5 × 105 into six-well plates and cultured to 90%
confluence, complete media is replaced with serum free media and cells
are cultured overnight until a monolayer is formed. A sterile 100 μl
pipette tip us used to make a linear scratch and dissociated cells washed
with cell culture media and cultured with complete media or adipocyte-
conditioned media. Images of was acquired at 0 and 48 h at ×100
magnification. The captured images were analysed using ImageJ
software. Breast cell migration and invasion was assessed using corning
transwell insert (8-μm pore size; Corning Inc.) without matrigel (Migration
assay) and with 1.0 mg/ml matrigel (Invasion assay) (BD Biosciences,
Bedford, MA, USA). Co-cultured and control cells were seeded at 5 × 104
cells in 300 μl of serum free media into the upper chamber of the
transwell plate with 10% FBS media in the bottom chamber. Cells were
cultured for 24 h for migration and 48 h for invasion. After removal of
non-invading cells, invading cells were fixed and stained by the Diff-Quik
kit (Sysmex, Seoul, Korea) and the number of migrating and invasion cells
was counted under a microscope in five random fields of each
membrane at ×100 magnification. All experiments were repeated at
least three times.
CD36/CD44 flow cytometry and annexin V/PI assay
To determine the proportion of CD36/CD44 expressing cells, cells co-
cultured and control cells were harvested and resuspended to ~1–5 × 106
cells/ml in ice cold PBS. Cells are fixed with 4% formaldehyde for 15 min
at RT. Cells are resuspended in 100 μl BSA/PBS and incubated with
primary antibodies against CD36 and CD44 and for 1 h at RT. Cells are
rinsed 3X and resuspended in ice cold PBS. Cells are incubated with Alexa
Fluor 488 and Alexa Fluor 647-conjugated secondary antibody for
another 30 min, rinsed and analysed. Cells are initially selected for FSC-A/
SSC-A gating followed by SSC-H/CD44-FITC gating, CD36-APC/FSC-H
gating and CD36-APC/CD44-FITC positive cell gating. To determine the
proportion of apoptotic cells, cells treated with specific inhibitors were
seeded at 4 × 105 cells and stained using Alexa Fluor 488 annexin V/Dead
cell apoptotic kit (Invitrogen, Paisley, UK) following manufacturers
instruction. Apoptotic cells were detected by flow cytometry using BD
FACSAria™ III (BD Biosciences, San Jose, USA).
Protein extraction and western blot
Protein were extracted from cells using RIPA buffer (GenDEPOT, TX, USA)
containing 1% protease inhibitor and 1% phosphatase inhibitor cocktail
(GenDEPOT) as lysis buffer. In total, 20 μg of extracted proteins is separated
by SDS-PAGE and transferred to a nitrocellulose membrane (GE Healthcare,
Chalfont St Giles, UK). Immunoblotting was performed as previously
described by Gyamfi et al.4 List of all primary antibodies and dilutions used
are indicated in Supplementary Table 6. All gels and blots were derived
from the same experiment and were processed in parallel.
RNA extraction and quantitative real-time PCR
Total RNA from co-cultured and control cells were extracted was isolated
using the RNeasy Kit (Qiagen, Valencia, CA, USA) following manufacturer’s
instruction. A one-step real-time PCR was performed with 50 ng of RNA
using the TOPreal One-step RT-qPCR kit (SYBR Green with high ROX)
(enzynomics, KR) according to the manufacturer’s instruction and analysed
with the StepOne Plus Real-time PCR system (Applied Biosystems, Foster
City, CA, USA). All reactions were performed in triplicate; with the
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase as an
internal control mRNA. All primers were initially evaluated for efficiency
using the Relative standard curve and the relative gene expression
evaluated by comparative CT method (2−ΔΔCT). Amplification primers are
listed in Supplementary Table 2.
Immunofluorescence
Immunofluorescence was performed as previous described by Gyamfi
et al. Briefly, cells are seeded on cover slide placed in co-culture insert
and co-cultured with adipocytes for 48 h. Cells was rinsed in PBS and
fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100
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and stained with appropriate primary antibodies. For double staining
experiments, antibodies were diluted together and incubated with cells
overnight at 4 °C. Goat Anti-Rabbit IgG (Alexa Fluor 647) and Goat Anti-
mouse IgG (Alexa Fluor 488) antibodies (Abcam) were used as secondary
antibodies. Counter staining of cell nuclei was performed using DAPI
(Invitrogen, Carlsbad, CA, USA). Stained cells were visualised using the
ZEISS LSM 710 microscope (ZEISS, Germany). Antibodies used included
mouse anti-E-cadherin 1:500 (Cell Signalling, Danvers, MA, USA), rabbit
anti-Vimentin 1:500 (Proteintech).
Luciferase reporter assay
For reporter assay, mock-CD36, CD36-expressing and CD36-knockdown
cells are transiently co-transfected with cignal-STAT3 reporter plasmid or
cignal-PPAR reporter plasmid (Cignal Lenti-PPAR Reporter, QIAGEN, Hilden,
Germany). Promoter activity is measured at specific time points (0, 1, 6, 12,
24 and 48 h). Promoter activity was determined using the Promega Dual-
Luciferase reporter assay system (Promega corporation, Madison, USA)
following manufacturers instruction and luciferase activity measured in the
Tecan™ microplate-Luminometer (Tecan Group Limited, Männedorf,
Switzerland). The constitutively expressed non-inducible Renilla luciferase
activity served as internal control for normalising transfection efficiencies.
Immunohistochemistry
Formalin fixed tissues sections are deparaffinized by passing sections
through xylene, followed by a series of decreasing concentration of
alcohol. Antigen retrieval was performed by immersing tissue sections in
10mM pre-heated citrate buffer (pH 6.0) and microwaved for 5 min and
cooled at RT for 20min. Endogenous peroxidase activity was quenched by
immersing samples in 3% H2O2 for 15min and incubated with anti-CD36
primary antibody diluted at 1:1000 and incubated at 4 °C overnight. The
slides are developed using the EnVision Dual Link System-HRP kit (DAKO)
according to the manufacturer’s instruction. All IHC results were examined
and scored from 1 to 4 based on their expression intensity and percentage
of stained cell population by two independent scientists.
Co-immunoprecipitation assay
Co-IP assay was performed using the Thermo Scientific co-IP kit following
the manufacturer’s protocol. Primary antibodies (2 μg of CD36) and (2 μg of
FABP4) were immobilised for 2 h using AminoLink Plus coupling resin at
4 °C. Cell lysate (500 μg of total protein) was pre-cleared by incubating with
control agarose resin for 1 h at 4 °C. Antibody coupled resin was then
incubated with pre-cleared protein lysate overnight at 4 °C. Resins were
washed and proteins eluted. Eluted protein was separated on SDS-PAGE
and analysed by western blot.
Identification of STAT3 binding sites and chromatin
immunoprecipitation (ChIP) assay
Two transcription factor binding site prediction tools, rVista (http://rvista.
dcode.org) and CONTRA v2 (http://www.dmbr.ugent.be/prx/bioit2-public/
contrav2/index.php), and NCBI sequence finder tool was used to identify
putative STAT3 transcription factor binding sites present in the CD36
promoter. Chromatin was isolated from cells after cross-linked by 1%
formaldehyde, using the Chromatin Extraction Kit (ab117152, Abcam-USA),
following manufacturers instruction. Isolated chromatin was sonicated for
10min and chromatin immunoprecipitation was done with the One-Step
Chip kit (Abcam, ab117138). Antibody recognising pSTAT3 (abcam, dilution
1:50) was used as the pull-down was used for the ChIP assay. The purified
DNA was analysed by real-time PCR with a PCR kit (Takara Bio Inc., Japan)
according to the manufacturer’s protocols. The primers for ChIP-qPCR are
provided in Supplementary Table 3.
Seahorse metabolic assay
Cells are cultured with/without adipocytes and seeded evenly at 40,000
cells/well in the XF24 cell culture plate and allowed to attach for 24 h. Cells
were assessed with the XF cell energy phenotype test, XF cell mito-stress
test, XF mito-fuel flex test and XF palmate-BSA FAO test (Agilent
Technologies, UK) following the manufacturers protocol. After each assay,
floating cells are recovered, centrifuged and attached cells lysed with RIPA
buffer. Protein concentration was determined using Pierce BCA protein
assay kit (Thermo Fisher Scientific) for normalisation.
Transfection and generation of stable cell lines
The full-length human CD36 (hCD36) cDNA was amplified with PCR using
specific primers and subcloned into the EcoR1 and XbaI sites of the pLVX-
EF1a-IRES-Puro (clontech) to generate the pLVX-EIP-CD36 plasmid.
Lentivirus expressing hCD36 was produced by transfecting HEK293T cells
(ATCC) with plasmids; pLVX-EIP-CD36, psPAX2 (Addgene, plasmid #1260)
and pMD2.G (Addgene, plasmid #12259) using DharmaFECT-Kb transfec-
tion reagent (GE Healthcare). Virus conditioned media was harvested after
48 h and cleared with filtration through 0.44 nm pore before use. To
generate stable CD36-expressing cells, cells were cultured with viral
conditioned media in 1:1 ration containing polybrene for 48 h. Monoclonal
CD36 expression cells were selected with 10 µg/ml puromycin over
14 days. To generate stable CD36-knockout MCF-7 and MDA-MB-468 cells,
we selected three CRISPR guide RNA targeting CD36 cloned into the
pLentiCRISPRv2 plasmid. Lentivirus expressing CD36 guide-RNAs was
produced by transfecting HEK293T cells with pLentiCRISPRv2 plasmid,
psPAX2 (Addgene, plasmid #1260) and pMD2.G (Addgene, plasmid
#12259) using DharmaFECT-Kb transfection reagent (GE Healthcare). Virus
conditioned media was harvested after 48 h and cleared with filtration
through 0.44 nm pore before use. To generate stable CD36-knockout cells,
MCF-7 and MDA-MB-468 cells were cultured with viral conditioned media
in 1:1 ratio containing polybrene for 48 h. Stable monoclonal CD36-
knockout cells were selected using 10 µg/ml puromycin over 14 days.
CRISPR guide RNA sequences are provided in Supplementary Table 2,
CD36 plasmid DNA amplification primers are provided in Supplementary
Table 4 and CD36 CDS amplification primers are provided in Supplemen-
tary Table 5.
GST pull-down assay
For bacteria GST pull-down assay, full human CD36 cDNA was cloned into
the pGEX-4T-3 plasmid and used to transform a BL21 bacteria. CD36-GST-
tagged protein expression was induced with 1mM IPTG and GST-tagged
CD36 purified by the GST SpinTrap colum (GE Healthcare, UK). For GST-
CD36 pull-down assay, proteins from control CD36-expressing and CD36-
knockout MCF-7 and MDA-468 breast cancer cells were mixed with GST-
tagged CD36 proteins and incubated at 4 °C for 4 h with rotating. Pull-
down proteins eluted with elution buffer and 1/20 of the extract was
subjected to SDS/PAGE and immunoblotting performed using anti-FABP4
antibody. For mammalian GST assay, CD36 cDNA was cloned into the
pcDNA3.1+ N-GST(Thrombin) plasmid and transfected into breast
cancer cells.
In vivo xenograft mouse model
All mouse studies were approved by the Institutional Animal Care and Use
Committee of Yonsei University, South Korea. Seven-week-old female Balb/
C Nude mice were purchased from Orient bio, South Korea. Mice were
housed for a week to allow for additional adjustment under semi-
pathogen free facility and were fed sterilised water and food. MDA-MB-231
cells were infected by firefly luciferase lentivirus and selected by
puromycin. In total, 3 × 106 cells diluted in 80 μl of PBS were injected
orthotopically into 8-week-old mice. Mice were randomly assigned to
experimental groups of five mice each and housed under the same
conditions. Group 1 (G1) were the control group and received no
treatment, group 2 (G2) were treated with the FABP4 inhibitor: BMS309403,
group 3 (G3) were treated with the CD36 inhibitor; SSO and group 4 (G4)
were treated with a combination of BMS309403 and SSO. FABP4 inhibitor
(BMS309403) were purchased from Selleckchem and CD36 inhibitor (SSO)
were purchased from Cayman. Following manufacturer’s instructions,
BMS309403 were dissolved in 10% 1-methyl-2-pyrrolidone, 5% cremophor,
2% ethanol and 83% PBS. SSO were dissolved in 10% DMSO, 40% PEG, 5%
Tween-80 and 45% PBS. In total, 15mg/kg dose BMS309403 were fed daily
by oral gavage and 40mg/kg dose SSO were Intraperitoneally injected into
mice twice in a week. The weight and survival condition of mice were
measured on every 3rd day. Tumour size estimation was done by
measuring the intensity of luciferin in each mouse twice in a week by IVIS
Lumina XRMS In vivo imaging system, PerkinElmer. To validate intensity of
luciferin XenoLight D-luciferin—potassium salt Bioluminescent Substrate,
PerkinElmer were dissolved in PBS. In total, 150 mg/kg Luciferin were
Intraperitoneally injected 10min before estimated intensity. Signals of
luciferin of each mouse were validated by Living image software,
PerkinElmer. After the 42 days, mice were sacrificed, and tumour nodules
excised and measured.
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Data availability and EMT score calculation
The referenced TCGA data in the study are available in a public
repository from the cBioPortal website (https://cbioportal.org), Morpheus
online tool (https://software.broadinstitute.org/morpheus/), GEPIA web-
site (http://gepia.cancer-pku.cn) and UALCAN website (http://ualcan.
path.uab.edu/cgi-bin/ualcan-res.pl). Gene expression profile for EMT
markers, fatty acid transmembrane transporters, fatty acid transporter
activity were done using gene set data available at the molecular
signature database (MsigDB) website (http://software.broadinstitute.org/
gsea/msigdb/genesets.jsp?collection=C5)36,37. A list of specifically used
gene set are listed in Table 3. EMT score was calculated using the
formula [EMT score= Sum of mesenchymal gene expression (CDH2, FN1,
SNAI1, SNAI2, TWIST1, TWIST2, VIM, ZEB1, ZEB2)− Sum of epithelial gene
expression (CDH1, CLDN4, CLDN7, MUC1, TJP3)]15. Hierarchical cluster-
ing, heatmap visualisations and correlation matrix visualisations were
generated using the Morpheus analysis platform. Clusters were obtained
using the average linkage method with 1-Pearson’s correlation
coefficient as the distance metric. Gene sets used in various heatmaps
and correlation matrixes are presented in Table 4.
Statistical analysis
All experiments were performed three times independently under similar
conditions. Results are shown as the means and the error bars represent
the standard error of the mean (SD), unless stated otherwise. Data were
analysed, and graphs plotted with GraphPad Prism version 6 software
(GraphPad Inc.). p values were calculated by Student’s t test was used to
compare differences between two groups and multiple analysis was
performed using analysis of variance (ANOVA). Multiple analysis of groups
was checked for after ANOVA using Bonferroni’s multiple comparison test.
p values of statistical significance are represented as *p ≤ 0.05, **p ≤ 0.001
and ***p < 0.0001.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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